查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750811

核子醫學市場規模、佔有率、趨勢分析報告：按產品、應用、最終用途、地區和細分市場預測，2025 年至 2030 年

Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics, Therapeutics), By Application (Cardiology, Neurology, Oncology), By End Use (Hospitals, Diagnostic Centers), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 170 Pages | 商品交期: 2-10個工作天內

價格

核子醫學市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球核子醫學市場規模預計到2030年將達到345.1億美元，2025年至2030年的複合年成長率為10.16%。

癌症和甲狀腺等慢性疾病的日益流行預計將推動市場成長。預測期內即將核准的幾種放射性藥物療法將成為市場的主要驅動力。例如，諾華公司於2022年3月獲得核准Pluvicto (Lu 177)用於治療成年攝護腺癌患者。

根據泛美衛生組織（PAHO）估計，2022年全球將新增約2,000萬例癌症病例，約1,000萬人死於癌症。生活方式改變、不健康飲食以及中低收入國家口腔衛生意識低下等因素是導致癌症流行最常見的原因。

核子醫學產品在診斷領域的日益普及，以及有助於增加放射性核種供應的新型發生器的核准，預計將推動成長。例如，2021年11月，EZAG公司在巴西獲得了巴西衛生管理局（ANVISA）對GalliaPharm的核准。這是一款鎵-68發生器，用於崩壞的鍺-68源中提取正電子發射鎵同位素，以製造G-68碘酸鹽注射液。這是巴西首款也是唯一核准用於製藥的鎵發生器。此類產品的核准將有助於開拓新興市場。

受新冠疫情影響，市場略有影響。 2020年第二季度，核能總署（IAEA）對核子反應爐醫用同位素進行了一項調查，以評估新冠疫情期間的供應鏈連續性。調查結果顯示，主要生產商仍在按照IAEA的安全標準繼續生產。

核子醫學市場報告重點

  • 根據產品類型，SPECT 領域佔據診斷市場的最大佔有率，因為它成本低、準確度高，且在各種應用中用途廣泛。
  • 由於前列腺癌 PYLARIFY PET 成像劑等新產品的核准和推出，預計 PET 領域在預測期內將經歷顯著成長。
  • 根據應用，腫瘤學將在 2024 年佔據市場主導地位。
  • 2024 年，北美佔據市場主導地位，佔有 42.87% 的佔有率，這得益於人們對當前治療方法的認知不斷提高、報銷政策優惠以及患者負擔能力的提高。
  • 由於預測期內慢性病盛行率上升、老年人口成長以及新產品核准，亞太地區預計將成為未來成長最快的地區。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章核子醫學市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 核子醫學市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析

第4章 核子醫學市場：依產品分類的評估與趨勢分析

  • 全球核子醫學市場：產品儀表板
  • 全球核子醫學市場：產品差異分析
  • 按產品分類的收益
  • 診斷
    • SPECT
    • PET
  • 治療方法
    • α發射體
    • BETA射線發射器
    • 放射線治療

第5章 核子醫學市場：按應用的評估與趨勢分析

  • 全球核子醫學市場：應用儀表板
  • 全球核子醫學市場：應用趨勢分析
  • 按用途分類的收益
  • 心臟病學
    • SPECT
    • PET
    • 治療應用
  • 神經病學
  • 腫瘤學
  • 甲狀腺
    • SPECT
    • 治療應用
  • 淋巴瘤
  • 骨轉移
    • SPECT
    • 治療應用
  • 內分泌腫瘤
  • 肺部掃描
  • 泌尿系統
  • 其他

第6章 核子醫學市場：依最終用途的估計和趨勢分析

  • 全球核子醫學市場：依最終用途分類的儀表板
  • 全球核子醫學市場：按最終用途進行的變化分析
  • 按最終用途分類的收益
  • 醫院
  • 診斷中心
  • 其他

第7章核子醫學市場：區域估計與趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • Key company market share analysis, 2024
    • GE Healthcare.
    • Jubilant Life Sciences Ltd
    • Nordion（Canada）, Inc.
    • Bracco Imaging SPA
    • The Institute for Radioelements（IRE）
    • NTP Radioisotopes SOC Ltd.
    • The Australian Nuclear Science and Technology Organization
    • EczacIbasI-Monrol
    • Lantheus Medical Imaging, Inc.
    • Eckert &Ziegler.
    • Mallinckrodt.
    • Cardinal Health.
Product Code: GVR-1-68038-086-6

Nuclear Medicine Market Growth & Trends:

The global nuclear medicine market size is expected to reach USD 34.51 billion by 2030, registering a CAGR of 10.16% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic diseases such as cancer & thyroid is anticipated to drive market growth. The impending approval of multiple radiopharmaceutical therapeutics during the forecast period will be a major driver for the market. For instance, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer.

According to the Pan American Health Organization (PAHO), in 2022, globally around 20 million new cases of cancer are estimated to be diagnosed, and around 10 million deaths occurred due to this disease. Factors like changing lifestyle, unhealthy diet, and less awareness about oral hygiene in low and middle-income countries is the most common cause of the prevalence of cancer.

Increasing adoption of nuclear medicine products in diagnosis and the approval of new generators to help increase the supply of radionuclides is expected to drive growth. For instance, in November 2021, EZAG received the Brazilian Health Authority Regulatory Agency's (ANVISA) approval for GalliaPharm in Brazil. It is a gallium-68 generator used to extract the positron-emitting isotope of gallium from a source of decaying germanium-68 for making G68 dotatate injection. This is the first and only gallium generator approved for pharmaceutical use in Brazil. The approval of such products contributes to the market growth in developing markets.

In light of the COVID-19 pandemic, the market was moderately impacted. A survey was conducted for reactor-based medical isotopes by International Atomic Energy Agency (IAEA) during the second quarter of 2020 to assess the continuity of the supply chain during the COVID-19 crisis. It was revealed that major producers continued with production in line with IAEA safety standards, as their operations were categorized as essential by their respective governments.

Nuclear Medicine Market Report Highlights:

  • By product type, the SPECT segment held the largest share of the diagnostics market due to low cost, high accuracy, and wide usage in different applications.
  • The PET segment is expected to grow lucratively over the forecast period due to the approval & launch of new products such as PYLARIFY PET imaging agent for prostate cancer.
  • By application, the oncology segment dominated the market in 2024.
  • North America dominated the market with a share of 42.87% in 2024, owing to increased awareness about current treatment therapies, favorable reimbursement policies, and improved patient affordability.
  • The Asia Pacific region is expected to be the fastest-growing region considerably in the future due to the rising prevalence of chronic diseases, rising geriatric population, and approval of new products during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and Application outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Nuclear Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of cancer and cardiovascular diseases
      • 3.2.1.2. Increasing application of radiopharmaceuticals/nuclear medicine
      • 3.2.1.3. Growing demand for accurate diagnostic methods
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Stringent regulations pertaining to production, storage, & usage
  • 3.3. Nuclear Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Nuclear Medicine Market: Product Estimates & Trend Analysis

  • 4.1. Global Nuclear Medicine Market: Product Dashboard
  • 4.2. Global Nuclear Medicine Market: Product Movement Analysis
  • 4.3. Global Nuclear Medicine Market By Product, Revenue
  • 4.4. Diagnostics
    • 4.4.1. Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. SPECT
      • 4.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. TC-99m
        • 4.4.2.2.1. TC-99m market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. TL-201
        • 4.4.2.3.1. TL-201 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.4. GA-67
        • 4.4.2.4.1. GA-67 markets estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.5. I-123
        • 4.4.2.5.1. I-123 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.6. Others
        • 4.4.2.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. PET
      • 4.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.2. F18
        • 4.4.3.2.1. F18 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.3. SR-82/RB-82
        • 4.4.3.3.1. SR-82/RB-82 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.4. PYLARIFY (piflufolastat F 18)
        • 4.4.3.4.1. PYLARIFY (piflufolastat F 18) markets estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.5. Illuccix (gallium Ga 68 gozetotide)
        • 4.4.3.5.1. Illuccix (gallium Ga 68 gozetotide)s market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.6. Others
        • 4.4.3.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Therapeutics
    • 4.5.1. Therapeutics market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Alpha Emitters
      • 4.5.2.1. Alpha emitters market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.2. RA-223
        • 4.5.2.2.1. RA-223 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.3. Others
        • 4.5.2.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Beta Emitters
      • 4.5.3.1. Beta emitters market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.2. I-131
        • 4.5.3.2.1. I-131 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.3. Y-90
        • 4.5.3.3.1. Y-90 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.4. SM-153
        • 4.5.3.4.1. SM-153 markets estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.5. Re-186
        • 4.5.3.5.1. Re-186 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.6. Lu-177
        • 4.5.3.6.1. Lu-177 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.7. Others
        • 4.5.3.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Brachytherapy
      • 4.5.4.1. Brachytherapy market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.4.2. Cesium-131
        • 4.5.4.2.1. Cesium-131 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.4.3. Iodine-125
        • 4.5.4.3.1. Iodine-125 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.4.4. Palladium-103
        • 4.5.4.4.1. Palladium-103 markets estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.4.5. Iridium-192
        • 4.5.4.5.1. Iridium-192 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.4.6. Others
        • 4.5.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Nuclear Medicine Market: Application Estimates & Trend Analysis

  • 5.1. Global Nuclear Medicine Market: Application Dashboard
  • 5.2. Global Nuclear Medicine Market: Application Movement Analysis
  • 5.3. Global Nuclear Medicine Market Estimates and Forecasts, By Application, Revenue (USD Million)
  • 5.4. Cardiology
    • 5.4.1. Cardiology market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. SPECT
      • 5.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. PET
      • 5.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Therapeutic Applications
      • 5.4.4.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Neurology
    • 5.5.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Oncology
    • 5.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Thyroid
    • 5.7.1. Thyroid market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. SPECT
      • 5.7.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. Therapeutic Applications
      • 5.7.3.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Lymphoma
    • 5.8.1. Lymphoma market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Bone Metastasis
    • 5.9.1. Bone metastasis market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.9.2. SPECT
      • 5.9.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.9.3. Therapeutic Applications
      • 5.9.3.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.10. Endocrine Tumor
    • 5.10.1. Endocrine tumor market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.11. Pulmonary Scans
    • 5.11.1. Pulmonary scans market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.12. Urology
    • 5.12.1. Urology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.13. Others
    • 5.13.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Nuclear Medicine Market: End Use Estimates & Trend Analysis

  • 6.1. Global Nuclear Medicine Market: End Use Dashboard
  • 6.2. Global Nuclear Medicine Market: End Use Movement Analysis
  • 6.3. Global Nuclear Medicine Market Estimates and Forecasts, by End Use, Revenue (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Diagnostic Centers
    • 6.5.1. Diagnostic centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Nuclear Medicine Market: Regional Estimates & Trend Analysis By Product, Application, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. GE Healthcare.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Jubilant Life Sciences Ltd
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Nordion (Canada), Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Bracco Imaging S.P.A
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. The Institute for Radioelements (IRE)
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. NTP Radioisotopes SOC Ltd.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. The Australian Nuclear Science and Technology Organization
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. EczacIbasI-Monrol
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Lantheus Medical Imaging, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Eckert & Ziegler.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Mallinckrodt.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
    • 8.3.15. Cardinal Health.
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America nuclear medicine market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S. nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe nuclear medicine market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 14 Europe nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Germany nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 17 Germany nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 20 UK nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 21 UK nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 23 France nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 24 France nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 26 Italy nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 29 Spain nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Denmark nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 32 Denmark nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Sweden nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 35 Sweden nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Norway nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 38 Norway nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific nuclear medicine market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 43 Aisa Pacific nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 44 China nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 45 China nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 46 China nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Japan nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 48 Japan nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 49 Japan nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 51 India nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 52 India nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 53 South Korea nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 54 South Korea nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 55 South Korea nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Australia nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 57 Australia nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 58 Australia nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Thailand nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 60 Thailand nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 61 Thailand nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America nuclear medicine market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 64 Latin America nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 65 Latin America nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Brazil nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 67 Brazil nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Mexico nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 70 Mexico nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 71 Mexico nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Argentina nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 73 Argentina nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 75 MEA nuclear medicine market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 77 MEA nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 78 MEA nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 79 South Africa nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 80 South Africa nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 86 UAE nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 89 Kuwait nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait nuclear medicine market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Nuclear medicine market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Nuclear medicine market snapshot
  • Fig. 10 Nuclear medicine market driver impact
  • Fig. 11 Global cancer cases projections-2030 (Number of new registered cases)
  • Fig. 12 Nuclear medicine market restraint impact
  • Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Value chain analysis
  • Fig. 16 Nuclear medicine market: Production of Tc-99 (SPECT radioisotopes)
  • Fig. 17 Nuclear medicine market: Production of 18F-FDG (PET radioisotopes)
  • Fig. 18 Company market share analysis
  • Fig. 19 Company market position analysis
  • Fig. 20 Company market position analysis
  • Fig. 21 Competitive dashboard analysis
  • Fig. 22 Regional network map
  • Fig. 23 Nuclear medicine market: Product outlook and key takeaways
  • Fig. 24 Nuclear medicine market: Product movement analysis
  • Fig. 25 Diagnostic products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 TC-99m market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 TL-201 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 GA-67 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 I-123 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Other SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 PET products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 F-18 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 SR-82/RB-82 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 PYLARIFY (piflufolastat F 18) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Illuccix (gallium Ga 68 gozetotide) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Therapeutic products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Alpha emitters market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 RA-223 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 I-131 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Y-90 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 SM-153 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Re-186 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Lu-177 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Brachytherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Cesium-131 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Iodine-125 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Palladium-103 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Iridium-192 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Nuclear medicine market: Application outlook and key takeaways
  • Fig. 56 Nuclear medicine market: Application movement analysis
  • Fig. 57 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Thyroid market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Lymphoma market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Bone metastasis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Endocrine tumor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Pulmonary scans market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Urology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Nuclear medicine market: End-use outlook and key takeaways
  • Fig. 68 Nuclear medicine market: End-use movement analysis
  • Fig. 69 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Diagnostic centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Global nuclear medicine market: Regional movement analysis
  • Fig. 73 Global nuclear medicine market: Regional outlook and key takeaways
  • Fig. 74 Global nuclear medicine market share and leading players
  • Fig. 75 North America, by country
  • Fig. 76 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 U.S. key country dynamics
  • Fig. 78 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Canada key country dynamics
  • Fig. 80 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Mexico key country dynamics
  • Fig. 82 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 UK key country dynamics
  • Fig. 85 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Germany key country dynamics
  • Fig. 87 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 France key country dynamics
  • Fig. 89 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Italy key country dynamics
  • Fig. 91 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Spain key country dynamics
  • Fig. 93 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Denmark key country dynamics
  • Fig. 95 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Sweden key country dynamics
  • Fig. 97 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Norway key country dynamics
  • Fig. 99 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 China key country dynamics
  • Fig. 102 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Japan key country dynamics
  • Fig. 104 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 India key country dynamics
  • Fig. 106 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Thailand key country dynamics
  • Fig. 108 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 South Korea key country dynamics
  • Fig. 110 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Australia key country dynamics
  • Fig. 112 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 Brazil key country dynamics
  • Fig. 115 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Argentina key country dynamics
  • Fig. 117 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 118 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 South Africa key country dynamics
  • Fig. 120 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 121 Saudi Arabia key country dynamics
  • Fig. 122 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 123 UAE key country dynamics
  • Fig. 124 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 125 Kuwait key country dynamics
  • Fig. 126 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 127 Market share of key market players- nuclear medicine market